Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05180240 · ClinicalTrials.gov registry record · Phase 2
Impact of CardiolRx on Myocardial Recovery in Patients With Acute Myocarditis
A Phase 2 study, sponsored by Cardiol Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 109
- Enrollment target
NCT05180240 is a Phase 2 study that has completed, run by Cardiol Therapeutics. The registered enrollment target is 109 participants.
The verdict
NCT05180240, a Phase 2 study, has completed, sponsored by Cardiol Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 109 participants
- Enrollment target
Study Summary
Multi-center, double-blind, placebo-controlled, parallel group design. Patients with myocarditis will be screened and, if eligible, randomized within 10 days of the diagnostic CMR to CardiolRx or placebo. CardiolRx is pharmaceutically produced Cannabidiol and is free of tetrahydrocannabinol (THC\<5 ppm). The treatment period is 12 weeks; a last follow-up visit is scheduled one week after the last treatment, 13 weeks after randomization. Study assessments include Cardiac Magnetic Resonance imaging (CMR), ECG monitoring, the Kansas City Cardiomyopathy Questionnaire (KCCQ), the Columbia-Suicide Severity Rating Scale (C-SSRS) as well as physical exams and laboratory tests. The primary and secondary outcome parameters are measured by CMR. Additional outcomes include clinical endpoints and changes in inflammatory and biomarkers.
Interventions
- DRUG CardiolRx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2022-07-28 |
| Est. Completion | 2025-02-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05180240
The ClinicalTrials.gov registry entry for NCT05180240 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cardiol Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CardiolRx is the first listed.
NCT05180240 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05180240 about?
NCT05180240 is a clinical study titled "Impact of CardiolRx on Myocardial Recovery in Patients With Acute Myocarditis". Multi-center, double-blind, placebo-controlled, parallel group design. Patients with myocarditis will be screened and, if eligible, randomized within 10 days of the diagnostic CMR to CardiolRx or placebo. CardiolRx is pharmaceutically produced Cannabidiol and is free of tetrahydrocannabinol (THC\<5...
What is the current status of trial NCT05180240?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 109 participants. The study started on 2022-07-28. Estimated completion is 2025-02-04.
What interventions are being tested in trial NCT05180240?
The interventions under investigation include: CardiolRx (DRUG).
Who is sponsoring clinical trial NCT05180240?
This trial is sponsored by Cardiol Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.